Security
Korro Bio, Inc. Common Stock · KRRO
KRRONASDAQCommon stockCurrentCIK 1703647Updated Oct 28, 2026
Name history
Frequency Therapeutics, Inc. · through Nov 6, 2023
KRRO price & chart
Loading TradingView…
NASDAQ:KRRO on TradingView ↗About the company
Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential f…
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
144 filing
144 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 161,550,000Source | 243,543,000Source | 163,446,000Source | 180,425,000Source | 249,588,000Source | 183,622,000Source | 202,207,000Source | 197,985,000Source | 113,506,000Source | 226,240,000Source | 221,663,000Source | 121,238,000Source |
| Property, Plant and Equipment, NetUSD | 24,398,000Source | 29,111,000Source | 7,477,000Source | 25,395,000Source | 24,704,000Source | 7,805,000Source | 26,676,000Source | 20,509,000Source | 8,164,000Source | 27,710,000Source | 15,665,000Source | 2,739,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 24,155,000Source | 63,207,000Source | 24,905,000Source | 33,612,000Source | 91,152,000Source | 61,697,000Source | 64,144,000Source | 138,804,000Source | 21,824,000Source | 55,643,000Source | 166,150,000Source | 51,954,000Source |
| Assets, CurrentUSD | 98,226,000Source | 152,783,000Source | 120,631,000Source | 102,634,000Source | 163,627,000Source | 120,163,000Source | 121,235,000Source | 145,655,000Source | 82,372,000Source | 131,532,000Source | 172,728,000Source | 87,493,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,927,000Source | 4,018,000Source | 5,595,000Source | 5,183,000Source | 4,425,000Source | 6,193,000Source | 4,358,000Source | 3,305,000Source | 6,247,000Source | 3,741,000Source | 3,015,000Source | 4,396,000Source |
| Operating Lease, Right-of-Use AssetUSD | 23,332,000Source | 24,018,000Source | 7,574,000Source | 23,510,000Source | 24,837,000Source | 7,816,000Source | 23,678,000Source | 25,947,000Source | 8,058,000Source | 23,836,000Source | 27,150,000Source | 28,980,000Source |
| Other Assets, NoncurrentUSD | 3,171,000Source | 2,110,000Source | 2,470,000Source | 3,213,000Source | 2,672,000Source | 2,346,000Source | 3,173,000Source | 2,468,000Source | 2,472,000Source | 2,797,000Source | 2,714,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 62,518,000Source | 63,911,000Source | 60,220,000Source | 65,322,000Source | 51,511,000Source | 63,989,000Source | 63,250,000Source | 46,627,000Source | 62,067,000Source | 65,825,000Source | 51,752,000Source | 52,043,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 9,000Source | 9,000Source | 14,000Source | 9,000Source | 9,000Source | 14,000Source | 9,000Source | 8,000Source | 9,000Source | 9,000Source | 8,000Source | 35,000Source |
| Additional Paid in CapitalUSD | 432,613,000Source | 424,436,000Source | 525,788,000Source | 430,660,000Source | 422,435,000Source | 523,085,000Source | 428,657,000Source | 353,912,000Source | 435,064,000Source | 426,724,000Source | 352,908,000Source | 331,023,000Source |
| Retained Earnings (Accumulated Deficit)USD | -333,804,000Source | -245,387,000Source | -422,387,000Source | -315,743,000Source | -224,388,000Source | -403,471,000Source | -289,973,000Source | -202,562,000Source | -383,846,000Source | -266,586,000Source | -183,005,000Source | -261,665,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 214,000Source | 574,000Source | -189,000Source | 177,000Source | 21,000Source | 5,000Source | 264,000Source | — | 212,000Source | 268,000Source | 0Source | -198,000Source |
| Liabilities and EquityUSD | 161,550,000Source | 243,543,000Source | 163,446,000Source | 180,425,000Source | 249,588,000Source | 183,622,000Source | 202,207,000Source | 197,985,000Source | 113,506,000Source | 226,240,000Source | 221,663,000Source | 121,238,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 14,638,000Source | 13,610,000Source | 12,628,000Source | 17,173,000Source | 12,324,000Source | 14,787,000Source | 12,881,000Source | 11,053,000Source | 11,937,000Source | 14,960,000Source | 19,483,000Source | 21,026,000Source |
| Operating Lease, Liability, CurrentUSD | 3,145,000Source | 0Source | 2,935,000Source | 2,425,000Source | 457,000Source | 2,801,000Source | 2,306,000Source | 1,235,000Source | 2,672,000Source | 1,284,000Source | 1,991,000Source | 2,021,000Source |
| Accounts Payable, CurrentUSD | 2,300,000Source | 5,950,000Source | 3,603,000Source | 5,163,000Source | 5,689,000Source | 1,957,000Source | 4,176,000Source | 4,657,000Source | 1,651,000Source | 3,992,000Source | 7,280,000Source | 3,114,000Source |
| Operating Lease, Liability, NoncurrentUSD | 41,523,000Source | 41,785,000Source | 39,278,000Source | 42,207,000Source | 38,004,000Source | 40,084,000Source | 42,879,000Source | 34,681,000Source | 40,814,000Source | 43,481,000Source | 31,216,000Source | 26,761,000Source |
| Other Liabilities, NoncurrentUSD | 1,532,000Source | 717,000Source | 1,504,000Source | 1,440,000Source | 1,183,000Source | 1,462,000Source | 1,442,000Source | 893,000Source | 1,481,000Source | 1,472,000Source | 1,053,000Source | 89,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 5,861,000Source | 5,459,000Source | 5,065,000Source | 5,659,000Source | 6,178,000Source | 9,850,000Source | 3,648,000Source | 5,161,000Source | 7,614,000Source | 6,171,000Source | 10,212,000Source | 5,891,000Source |
| Deferred Revenue, CurrentUSD | 3,332,000Source | 2,201,000Source | 1,025,000Source | 3,926,000Source | — | 179,000Source | 2,751,000Source | — | 0Source | 3,513,000Source | — | — |
| Deferred Revenue, NoncurrentUSD | 4,825,000Source | 7,799,000Source | 6,810,000Source | 4,502,000Source | — | 7,656,000Source | 6,048,000Source | — | 7,835,000Source | 5,912,000Source | — | — |
| Long-term Debt, Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 10,000,000Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -19,625,000Source | -23,387,000Source | -117,260,000Source | -83,581,000Source | -81,172,000Source | -81,580,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 19,831,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -969,000Source | 228,000Source | -727,000Source | 1,696,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -153,000Source | 99,000Source | -2,311,000Source | -1,341,000Source | 3,100,000Source | -677,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -16,074,000Source | -24,452,000Source | -78,561,000Source | -60,074,000Source | -67,283,000Source | -58,237,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -32,240,000Source | 32,781,000Source | 43,993,000Source | -123,347,000Source | 11,164,000Source | 31,133,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 21,000Source | 119,000Source | 518,000Source | 17,902,000Source | 7,836,000Source | 0Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 88,212,000Source | 172,000Source | 685,000Source | 69,355,000Source | 187,761,000Source | -577,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | -2,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 39,873,000Source | 8,501,000Source | -33,819,000Source | -114,070,000Source | 131,642,000Source | -27,681,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 914,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 48,000Source | 0Source | 1,000Source | 141,000Source | 27,000Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -25,000Source | 0Source | 64,000Source | -4,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,825,000Source | 1,273,000Source | 2,703,000Source | 1,998,000Source | 2,731,000Source | 1,761,000Source | 7,655,000Source | 4,462,000Source | 2,381,000Source | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | — | — |
| DepreciationUSD | — | — | 1,200,000Source | 900,000Source | 400,000Source | 1,200,000Source | 380,000Source | 1,225,000Source | 4,280,000Source | 3,565,000Source | 3,630,000Source | 2,766,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | — | -5,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | -63,000Source | -357,000Source | -65,000Source | — |
| General and Administrative ExpenseUSD | — | — | 6,507,000Source | 7,328,000Source | 6,522,000Source | 7,294,000Source | 7,485,000Source | 7,831,000Source | 28,159,000Source | 30,545,000Source | 27,284,000Source | 33,584,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -9,000Source | 108,000Source | 1,000Source | 95,000Source | 0Source | 637,000Source | 141,000Source | 27,000Source | -2,000Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 1,327,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,061,000Source | -20,999,000Source | -18,916,000Source | -25,770,000Source | -19,625,000Source | -23,387,000Source | -117,260,000Source | -83,581,000Source | -81,172,000Source | -81,580,000Source |
| Operating ExpensesUSD | — | — | 20,327,000Source | 23,292,000Source | 20,110,000Source | 28,662,000Source | 20,436,000Source | 27,570,000Source | 128,247,000Source | 94,181,000Source | 84,534,000Source | 83,002,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 4,802,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,176,000Source | 2,284,000Source | 1,302,000Source | 1,433,000Source | 906,000Source | 1,633,000Source | 5,232,000Source | 8,470,000Source | 3,389,000Source | 1,056,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 83,154,000Source | 0Source | — | 0Source | 117,250,000Source | 60,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 17,000Source | 172,000Source | 685,000Source | 1,970,000Source | 702,000Source | — |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | — | — | — | 3,000Source |
| Restructuring CostsUSD | — | — | — | — | — | 1,233,000Source | 41,000Source | — | 3,627,000Source | — | — | — |
| Unrealized Gain (Loss) on Investments | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | 6,392,000Source | 2,271,000Source | — | 0Source |
| Operating Income (Loss)USD | — | — | -19,237,000Source | -23,292,000Source | -20,110,000Source | -27,202,000Source | -20,436,000Source | -25,020,000Source | -121,855,000Source | -91,910,000Source | -84,534,000Source | -83,002,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,176,000Source | 2,284,000Source | 1,302,000Source | 1,433,000Source | 906,000Source | 1,633,000Source | 5,232,000Source | 8,470,000Source | 3,389,000Source | 1,056,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -18,061,000Source | -21,008,000Source | -18,808,000Source | -25,769,000Source | -19,530,000Source | -23,387,000Source | -116,623,000Source | -83,440,000Source | -81,145,000Source | -81,582,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -9,000Source | 108,000Source | 1,000Source | 95,000Source | 0Source | 637,000Source | 141,000Source | 27,000Source | -2,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,061,000Source | -20,999,000Source | -18,916,000Source | -25,770,000Source | -19,625,000Source | -23,387,000Source | -117,260,000Source | -83,581,000Source | -81,172,000Source | -81,580,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.92Source | -2.26Source | -1.07Source | -2.74Source | -1.69Source | -2.49Source | -12.48Source | -9.37Source | -53.08Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | -1.92Source | -2.26Source | -1.07Source | -2.74Source | -1.69Source | -2.49Source | -12.48Source | -9.37Source | -53.08Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 9,391,559Source | 9,303,218Source | 17,618,441Source | 9,390,542Source | 11,598,717Source | 9,384,266Source | 9,395,402Source | 8,920,561Source | 1,529,321Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 9,391,559Source | 9,303,218Source | 17,618,441Source | 9,390,542Source | 11,598,717Source | 9,384,266Source | 9,395,402Source | 8,920,561Source | 1,529,321Source | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 637,000Source | 141,000Source | 27,000Source | -2,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | — | -5,000Source |
| General and Administrative ExpenseUSD | — | — | 6,507,000Source | 7,328,000Source | 6,522,000Source | 7,294,000Source | 7,485,000Source | 7,831,000Source | 28,159,000Source | 30,545,000Source | 27,284,000Source | 33,584,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -117,816,000Source | -83,500,000Source | — | -81,586,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 961,000Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 961,000Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 1,327,000Source |
| Operating ExpensesUSD | — | — | 20,327,000Source | 23,292,000Source | 20,110,000Source | 28,662,000Source | 20,436,000Source | 27,570,000Source | 128,247,000Source | 94,181,000Source | 84,534,000Source | 83,002,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 4,802,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | — | — | — | 3,000Source |
| Research and Development ExpenseUSD | — | — | 13,820,000Source | 15,964,000Source | 13,588,000Source | 20,135,000Source | 12,951,000Source | 19,739,000Source | 65,575,000Source | 63,636,000Source | 57,250,000Source | 49,418,000Source |
| Restructuring CostsUSD | — | — | — | — | — | 1,233,000Source | 41,000Source | — | 3,627,000Source | — | — | — |
| Total Revenue | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
krro-ex99_1.htm · 8-K · 2026-10-22
Exhibit 99.1 Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold KRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%, highlighting its potential to reduce toxic protein accumulation in the liver Best-in-class preclinical profile sup…
Read attachment ↗krro-ex99_1.htm · 8-K · 2026-10-05
Exhibit 99.1 Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background Administered a single dose of 2mg/kg to the first cohort of healthy volunteers Expected to start dosing in UCD patients in the first half of 2027 with an interim readout expected in the second half of 2027 CAMBRIDGE, Mass., Oct. 5, 2026 - Korro Bio, Inc. (Kor…
Read attachment ↗krro-ex4_1.htm · 8-K · 2026-08-06
EX-4.1 2 krro-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II…
Read attachment ↗krro-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation from the European Medicines Agency (EMA) for KRRO-121 for patients with urea cycle disorders (UCDs) Nominated KRRO-111 as development candidate for the…
Read attachment ↗krro-ex99_1.htm · 8-K · 2026-05-19
EX-99.1 2 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) • Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs • Demonstrated >90% editing of SERPINA1 transcript in vivo translating into ~90% repaired functional alpha-1 antitrypsin (AAT) protein in plasma in a…
Read attachment ↗krro-ex99_2.htm · 8-K · 2026-05-19
EX-99.2 3 krro-ex99_2.htm EX-99.2 May 2026 Corporate Presentation Exhibit 99.2 Forward-Looking Statement and Disclaimers CONFIDENTIAL Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions or strategies of Korr…
Read attachment ↗